Pregabalin and Ankle Swelling
Yes, oral pregabalin commonly causes peripheral edema including ankle swelling, which is a well-documented dose-dependent adverse effect occurring in approximately 6% of patients in controlled trials.
Mechanism and Incidence
Pregabalin-induced peripheral edema is a recognized adverse effect that occurs through mechanisms independent of cardiovascular dysfunction. 1 The FDA label explicitly states that pregabalin treatment causes peripheral edema, with an incidence of 6% in pregabalin-treated patients compared to 2% in placebo-treated patients in controlled clinical trials. 1
Clinical Characteristics
The edema typically manifests as:
- Swelling in the lower extremities, particularly ankles, legs, and feet 2
- Dose-dependent occurrence, with higher frequencies at increased dosages 1
- Not associated with laboratory changes suggesting renal or hepatic dysfunction 1
- Generally mild severity, though can be clinically significant 3
Important Clinical Considerations
Withdrawal rates due to peripheral edema are relatively low (0.5% of pregabalin patients versus 0.2% of placebo patients), indicating most cases are manageable. 1
Risk is substantially increased when pregabalin is combined with thiazolidinedione antidiabetic agents. In diabetic peripheral neuropathy patients, peripheral edema occurred in 19% of patients taking both medications versus 8% taking pregabalin alone and 3% taking thiazolidinediones alone. 1 This represents a critical drug interaction requiring caution.
The edema is reversible upon dose reduction or discontinuation. Case reports demonstrate complete resolution within 2 weeks of stopping pregabalin. 2
Comparative Evidence
A direct comparison study substituting gabapentin with pregabalin at one-sixth the gabapentin dose showed significantly increased peripheral edema with pregabalin compared to gabapentin (P < 0.05), though the side effects remained mild enough to continue medication. 4
A systematic meta-analysis of 38 randomized controlled trials confirmed peripheral edema as one of 20 adverse events significantly associated with pregabalin, with edema appearing according to a selective dose-response pattern. 5
Management Approach
When peripheral edema develops:
- Reduce the pregabalin dose to the minimum effective level 3
- Consider gradual tapering if edema is severe 2
- Exercise particular caution in patients with NYHA Class III or IV heart failure, though short-term trials showed no association between peripheral edema and cardiovascular complications 1
- Monitor closely when co-prescribing with thiazolidinediones or ACE inhibitors 1
The edema does not require discontinuation in most cases unless it becomes dose-limiting or significantly impacts quality of life. 1, 4